RTTNews | Jul 21, 2020 10:27AM EDT

10:26 Tuesday, July 21, 2020 (RTTNews.com) - Shares of Dynavax Technologies Corp. (DVAX) are currently losing nearly 12% on Tuesday morning despite no stock-specific news.

DVAX is currently trading at $10.33, down $1.37 or 11.71%, on the Nasdaq.

On Monday, in an SEC filing, the company announced that Senior Vice President Robert Janssen sold 50,000 shares of Dynavax Technologies stock in a transaction that occurred on Friday, July 17th. The shares were sold at an average price of $11.09, for a total transaction of $554,500.

Dynavax Technologies is a biopharmaceutical company that focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older.

Meanwhile, China-based Sinovac Biotech Ltd. (SVA), which is developing CoronaVac for treatment of coronavirus, has collaborated with Dynavax to evaluate CoronaVac in combination with Dynavax's advanced adjuvant, CpG 1018.

Read the original article on RTTNews ( https://www.rttnews.com/3112842/stock-alert-dynavax-down-12.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2020 RTTNews.com All Rights Reserved